Natera stock trades at EUR 359.55 with a minus 296.1 P/ E

Published on 10/09/2026 at 19:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 752.75 million versus USD 661.24 million expected. Natera stock costs EUR 359.55 on October 9, 2026 after EUR 348.60.

Key points in brief

Natera stock was EUR 359.55 at Lang & Schwarz on October 9, 2026 at 7:38 p.m. CEST, plus 3.14 percent versus the EUR 348.60 prior close.
The company reported USD 752.75 million in second-quarter 2026 revenue versus USD 661.24 million expected.
Barclays raised its Natera target from USD 340.00 to USD 475.00 on October 7, 2026.
Natera's market capitalization was USD 57.6 billion, with a minus 296.1 P/E and 0.00 percent dividend yield.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) was trading at EUR 359.55 at Lang & Schwarz on October 9, 2026 at 7:38 p.m. CEST, plus 3.14 percent versus the prior close of EUR 348.60. The stock's trailing P/E was minus 296.1, putting valuation and operating growth on the same screen for investors.

Revenue sets the operating baseline

MarketBeat reported that Natera generated USD 752.75 million in the second quarter of 2026 against analyst expectations of USD 661.24 million. The comparison puts the revenue gap at USD 91.51 million, or 13.84 percent above consensus.

The second-quarter net loss was USD 66.97 million and diluted loss per share was USD 0.47, while operating margin stood at minus 10.00 percent for the same period. Operating cash flow reached USD 54.79 million in the second quarter, giving the quarterly revenue figure a cash-flow counterweight.

Barclays target reaches USD 475

According to Aktiencheck on October 7, 2026, Barclays raised its Natera price target from USD 340.00 to USD 475.00 and kept an overweight rating. The new target is 17.99 percent above the USD 402.53 primary-market price shown by the finance quote on October 9, 2026.

Natera operates in medical diagnostics and research, with molecular testing services spanning women's health, oncology and organ health. Its trailing P/E remains negative because the company reported a net loss in the second quarter, so revenue growth is the clearer operating measure in this report.

Comparison with peers

NTRA (Nasdaq, USD): plus 3.14 percent, P/E minus 296.1, market capitalization USD 57.6 billion.

Guardant Health (Nasdaq, USD): plus 1.47 percent, P/E minus 48.1, market capitalization USD 22.5 billion.

Myriad Genetics (Nasdaq, USD): plus 2.50 percent, P/E minus 3.6, market capitalization USD 406.6 million.

Next report date is November 5

ToAlpha lists November 5, 2026 as Natera's next earnings date. The scheduled report will give investors a fresh test of whether quarterly revenue can keep expanding from the USD 752.75 million second-quarter base.

After-hours price stays above prior close

Natera was trading at EUR 359.55 at Lang & Schwarz on October 9, 2026 at 7:38 p.m. CEST, after the Xetra close and plus 3.14 percent versus the EUR 348.60 Lang & Schwarz prior close on October 8, 2026. The quote's bid was EUR 358.70 and its ask was EUR 360.40.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.